Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin

In the Persantine-Aspirin Reinfarction Study, Part II (PARIS II), 3,128 persons who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously, were randomized into two groups: dipyridamole (Persantine) plus aspirin (n = 1,563) and placebo (n = 1,565). The average length of follow-up was 23.4 months. Prespecified primary end points were coronary incidence (definite nonfatal myocardial infarction plus death due to recent or acute cardiac event), coronary mortality (death due to recent or acute cardiac event) and total mortality, each at 1 year of patient follow-up and at the end of the study. Coronary incidence in the Persantine plus aspirin group was significantly lower than in the placebo group, both at 1 year (30% reduction) and at the end of the study (24% reduction). The statistically significant differences in coronary incidence, at 1 year and at the end of the study, in favor of the combination treatment remained after adjustment for multiple baseline variables and adjustment for multiple testing (three end points for two time periods). Although there were reductions for other end points, these differences were not statistically significant. Coronary mortality was 20% lower in the Persantine plus aspirin group compared with the placebo group at 1 year, and 6% lower overall. Total mortality in the treated group compared with the placebo group was 11% lower at 1 year and 3% lower overall. The reduced rates of coronary incidence largely reflected lower rates of definite nonfatal myocardial infarction in the Persantine plus aspirin group. Several subgroups were defined a priori and at the end of the study. The beneficial effect of Persantine plus aspirin compared with placebo for coronary incidence tended to be greater for the following groups of patients: those who had a non-Q wave infarct; those who were not taking digitalis; those who were receiving beta-receptor blocking drugs at baseline; those who were in New York Heart Association functional class I; those who had had only one myocardial infarction; or those who were enrolled in the study early, that is within 85 days of the qualifying myocardial infarction.

This article has been cited by other articles:

				T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF]

				B. M. Massie Aspirin Use in Chronic Heart Failure: What Should We Recommend to the Practitioner? J. Am. Coll. Cardiol., September 20, 2005; 46(6): 963 - 966. [Abstract] [Full Text] [PDF]

				K Dubey, D K Balani, and K K Pillai Potential adverse interaction between aspirin and Lisinopril in hypertensive rats Human and Experimental Toxicology, March 1, 2003; 22(3): 143 - 147. [Abstract] [PDF]

				M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, and H. Arnesen Warfarin, Aspirin, or Both after Myocardial Infarction N. Engl. J. Med., September 26, 2002; 347(13): 969 - 974. [Abstract] [Full Text] [PDF]

				G.Y.H. Lip and C.R. Gibbs Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review QJM, July 1, 2002; 95(7): 461 - 468. [Abstract] [Full Text] [PDF]

				J. G F Cleland, J. John, J. Dhawan, and A. Clark What is the optimal medical management of ischaemic heart failure? Br. Med. Bull., October 1, 2001; 59(1): 135 - 158. [Abstract] [Full Text] [PDF]

				J. A. Cairns, P. Theroux, H. D. Lewis Jr., M. Ezekowitz, and T. W. Meade Antithrombotic Agents in Coronary Artery Disease Chest, January 1, 2001; 119(1_suppl): 228S - 252S. [Full Text] [PDF]

				D. Hall The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1808 - 1812. [Full Text] [PDF]

				T. Stys, W. E. Lawson, G. C. Smaldone, and A. Stys Does Aspirin Attenuate the Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Heart Failure? Arch Intern Med, May 22, 2000; 160(10): 1409 - 1413. [Abstract] [Full Text] [PDF]

				G. W. Albers Choice of endpoints in antiplatelet trials: Which outcomes are most relevant to stroke patients? Neurology, March 14, 2000; 54(5): 1022 - 1028. [Abstract] [Full Text] [PDF]

				J. L. Wilterdink and J. D. Easton Dipyridamole Plus Aspirin in Cerebrovascular Disease Arch Neurol, September 1, 1999; 56(9): 1087 - 1092. [Abstract] [Full Text] [PDF]

				J. He, P. K. Whelton, B. Vu, and M. J. Klag Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials JAMA, December 9, 1998; 280(22): 1930 - 1935. [Abstract] [Full Text] [PDF]

				M. Eccles, N. Freemantle, J. Mason, and t. N. o. E. A. G. D. Group North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care BMJ, April 25, 1998; 316(7140): 1303 - 1309. [Full Text]

				S. Kaplan, A. Kaplan, K. F. Marcoe, W. P. Hammond, L. D. Fisher, and L. R. Sauvage Citric Acid Enhances the Antithrombotic Effect of Aspirin in Many Aspirin-Resistant Subjects Clinical and Applied Thrombosis/Hemostasis, January 1, 1997; 3(1): 54 - 57. [Abstract] [PDF]

				J. P. De La Cruz, A. Moreno, M. Muñoz, J. M. G. Campos, and F. S. De La Cuesta Effect of Aspirin Plus Dipyridamole on the Retinal Vascular Pattern in Experimental Diabetes Mellitus J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 454 - 459. [Abstract] [Full Text]

				E. J. Weiss, P. F. Bray, M. Tayback, S. P. Schulman, T. S. Kickler, L. C. Becker, J. L. Weiss, G. Gerstenblith, and P. J. Goldschmidt-Clermont A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary Thrombosis N. Engl. J. Med., April 25, 1996; 334(17): 1090 - 1094. [Abstract] [Full Text] [PDF]

				Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]

				H.W. Heiss, H. Just, D. Middleton, and G. Deichsel Reocclusion Prophylaxis with Dipyridamole Combined with Acetylsalicylic Acid Following PTA Angiology, April 1, 1990; 41(4): 263 - 269. [Abstract] [PDF]